|Articles|March 1, 2020
- Pharmaceutical Executive-03-01-2020
- Volume 40
- Issue 3
Pharmaceutical Executive, March 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
The Multichannel Reach: Balancing the Local and Global Voiceover 5 years ago
Market Access: From Being to Becomingover 5 years ago
Consider Data Before It’s a Problemover 5 years ago
Multichannel Marketing: Integrating Omnichannelover 5 years ago
Feds Target Biosimilar Anticompetitive Practicesover 5 years ago
Blood Feud Divides Europe Over Plasma Shortfallsover 5 years ago
Social Media’s Influence in Messaging Mixover 5 years ago
Habib Bennaceur: Following the Scienceover 5 years ago
A Bad Deal with Data?over 5 years ago
Country Report: United Arab EmiratesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
